psilocybin

A study examines the efficacy and safety of psilocybin in treating major depression that has not responded to conventional treatments. The research focuses on its potential as a therapeutic intervention for this specific mental health condition.

More states are expanding PTSD treatment options for first responders by adopting laws that include medical marijuana protections and psychedelic therapy research. Maryland and Ohio have enacted measures to support mental health, while Connecticut and Missouri are exploring psilocybin and ibogaine therapies for eligible first responders and veterans.

A California father pleaded guilty to drug charges for involving his two sons in an illegal psychedelic mushroom business, including distributing psilocybin to minors. His defense attorney disputed the severity of the charges, claiming doses were minimal and the children showed no adverse effects.

A new study estimates that up to 8 million Americans, or 2.8% of the U.S. population, have used psilocybin, commonly known as psychedelic mushrooms.

North Carolina lawmakers propose Senate Bill 1018 to allocate $5.4 million for researching psychedelic medicines like psilocybin and MDMA to treat PTSD and depression in veterans, first responders, and trauma-impacted populations. The bill has bipartisan support and aligns with a federal executive order to fast-track FDA review of psychedelic therapies.

An illegal drug operation was uncovered during a multi-county murder investigation in North Carolina. Rusty Johnson was fatally shot in Catawba County, and Thomas Christopher Banks was arrested for his murder. A psilocybin grow operation and drugs were found in Banks' home, leading to the arrest of Joshua Donald Burns on drug-related charges.

Joshua Donald Burns was arrested and charged with drug-related offenses after law enforcement discovered a psilocybin grow operation, methamphetamine, marijuana, and firearms during a manhunt for murder suspect Thomas Christopher Banks. Investigators from multiple agencies executed a search warrant at a Vale residence linked to Burns, leading to his detention at the Harven A. Crouse Detention Center.

Scientists are exploring synthetic modifications of natural psychedelic compounds like ibogaine and psilocybin to reduce risks and enhance therapeutic benefits. A yellow mushroom in China's Yunnan province induces consistent 'lilliputian hallucinations,' sparking interest in engineering safer, more effective psychedelics.

A study suggests that cocaine addicts could quit after a single dose of magic mushrooms. The study implies a potential breakthrough in addiction treatment. Magic mushrooms contain psilocybin, which may aid in quitting cocaine.

A study suggests that a single dose of magic mushrooms could help cocaine addicts quit. The study's findings indicate a potential breakthrough in treating addiction. Magic mushrooms contain the psychoactive compound psilocybin, which may aid in addiction recovery.

A new clinical trial shows that a single dose of psilocybin could be an effective treatment for cocaine addiction, with participants who received psilocybin being more likely to abstain from cocaine than those who received a placebo. The study was published in Jama Network Open and involved 19 participants who received psilocybin and 17 who received a placebo. Psilocybin is found in magic mushrooms.

Simone Stolzoff's book How to Not Know explores using psilocybin to treat OCD, also known as the doubting disorder. The book delves into the potential benefits of magic mushrooms in alleviating uncertainty associated with OCD. This approach may offer a new perspective on treating the condition.

A study focused on psilocybin, a psychedelic compound found in magic mushrooms, to understand how it changes the brain. The research aims to uncover the effects of psychedelic trips on the brain. This breakthrough brings science closer to understanding the neural impacts of psilocybin.

The FDA granted fast-track review to three companies studying psychedelic therapies for depression and PTSD, with two focusing on psilocybin for treatment-resistant depression and major depressive disorder. This move aligns with the Trump administration's push for potential approval of psychedelic treatments.

The FDA announced ultra-fast review timelines for three psychedelic drugs, including psilocybin and methylone, following an executive order by the Trump administration to accelerate access to psychedelics for mental health treatments. The move aligns with growing support from Trump allies and Health Secretary Robert F. Kennedy Jr.'s advocacy for psychedelic therapies.

President Trump signed an executive order to fast-track psychedelic drug research after a text exchange with Joe Rogan, accelerating federal review of substances like ibogaine and LSD. The policy shift, led by Health Secretary Robert F. Kennedy Jr., aims to expedite FDA approvals and address mental health challenges, particularly for veterans.

President Trump signed an executive order to fast-track research, funding, and potential FDA approval of psychedelic drugs like psilocybin and MDMA for treating PTSD, depression, and addiction. Supporters, including veterans' advocates and medical analysts, highlight potential benefits for treatment-resistant cases, while critics warn about insufficient safety and efficacy evidence.

President Trump signed an order to accelerate the review of psychedelics for treating mental health disorders, specifically endorsing psilocybin and ibogaine. The order aims to expedite research and regulatory processes for these substances.

Veteran Jesse Gould, who developed PTSD after three combat deployments in Afghanistan, turned to psilocybin retreats instead of long-term medication. Researchers suggest psilocybin may help with trauma but caution against expanded access without FDA approval.

A study published in Nature reveals that psychedelics like psilocybin, LSD, and ayahuasca alter brain connectivity in similar ways. The research, based on hundreds of brain scans, suggests shared mechanisms among these substances.